Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.56 USD
+0.12 (8.33%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.55 -0.01 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.56 USD
+0.12 (8.33%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.55 -0.01 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Zacks News
Pacific Biosciences (PACB) Upgraded to Buy: Here's Why
by Zacks Equity Research
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PacBio (PACB) Q2 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
PacBio's (PACB) Product revenues decline in the second quarter of 2024. However, Consumable and Service and other revenues increase year over year.
Compared to Estimates, Pacific Biosciences (PACB) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 16.67% and 11.12%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 16.67% and 1.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.05, representing no change from its previous close.
Pacific Biosciences of California (PACB) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Pacific Biosciences of California (PACB) concluded the recent trading session at $1.88, signifying a +1.62% move from its prior day's close.
PacBio's (PACB) Revio System to Boost Novogene's German Lab
by Zacks Equity Research
PacBio (PACB) announces that Novogene is set to use PACB's Revio long-read sequencing system to expand the capabilities of its new lab in Munich, Germany.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
PacBio (PACB) and Form Bio to Boost AAV Industry Development
by Zacks Equity Research
PacBio (PACB) and Form Bio collaborate to form an expert AAV Working Group to introduce essential tools for AAV development and research professionals.
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.37, indicating a +0.74% shift from the previous trading day.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pacific Biosciences of California (PACB) closed the most recent trading day at $1.65, moving -1.5% from the previous trading session.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Pacific Biosciences of California, Inc. (PACB) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Pacific Biosciences (PACB) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
by Zacks Equity Research
PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.
Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -22.22% and 2.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
by Zacks Equity Research
Despite strength in Revio and Onso platforms, an increasing number of customers delaying instrument purchases is likely to have dampened PacBio's (PACB) top line in the first quarter.
Investors Heavily Search Pacific Biosciences of California, Inc. (PACB): Here is What You Need to Know
by Zacks Equity Research
Pacific Biosciences (PACB) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Cigna (CI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of 4.86% and 1.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks
by Zacks Equity Research
Pacific Biosciences (PACB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Pacific Biosciences (PACB) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PacBio (PACB) Preliminary Q1 Revenues Dampened by Purchase Delays
by Zacks Equity Research
PacBio's (PACB) revenue growth in the first quarter is likely to have been hampered by an increasing number of customers delaying instrument purchases and softness in consumable shipments.